stockportfolio.pro
EyePoint, Inc. (EYPT)
Healthcare · Biotechnology · NasdaqGM
EyePoint, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.54M | $2.96M | $4.57M | $20.36M | $34.44M | $36.94M | $41.40M | $46.02M | $43.27M | $31.37M |
| Gross profit | — | — | — | — | — | — | $33.08M | $41.39M | $39.56M | $29.30M |
| Net income | $-18.48M | $-53.17M | $-86.13M | $-56.79M | $-45.39M | $-58.42M | $-102.25M | $-70.80M | $-130.87M | $-231.96M |
| Net margin | -245.2% | -1795.7% | -1884.2% | -278.9% | -131.8% | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
Source: EyePoint, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of EyePoint, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track EYPT in your portfolio →
EyePoint, Inc. financial history by metric
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
EyePoint, Inc. — frequently asked questions
What is EyePoint, Inc.'s revenue?
EyePoint, Inc. (EYPT) reported revenue of $31.37M for fiscal year 2025, down 27.5% from the prior year, according to its SEC filings.
Is EyePoint, Inc. profitable?
No — EYPT reported a net loss of $-231.96M in fiscal 2025.
What is EYPT's P/E ratio?
EyePoint, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is EyePoint, Inc. growing?
EYPT's revenue grew at roughly -1.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does EyePoint, Inc. have?
As of fiscal year 2025, EYPT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is EyePoint, Inc.'s gross margin?
EYPT's gross margin was 93.4% in fiscal 2025 — gross profit of $29.30M on revenue of $31.37M.
What is EyePoint, Inc.'s market cap?
EyePoint, Inc. (EYPT) has a market capitalization of about $1.03B, based on the latest data in our nightly-refreshed cache.
When does EyePoint, Inc.'s fiscal year end?
EYPT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from EyePoint, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.